Longevity and precision medicine driving the agenda at Abu Dhabi Global Health Week
ABU DHABI, UAE, April 10, 2025 /PRNewswire/ -- With rising global demand for more personalised and effective healthcare solutions, the Department of Health - Abu Dhabi (DoH) , the regulator of the healthcare sector in the emirate, is hosting global leaders in health, research, policy, and technology to address the challenge of helping people to live not just longer, but healthier lives.
During the upcoming Abu Dhabi Global Health Week (ADGHW), a global initiative aimed at advancing longevity science and precision medicine will be released, expected to set a new standard for international collaboration, innovation, and investment in next-gen medical technologies.
The initiative is designed to drive the widespread adoption of personalised healthcare approaches and promote research into extending healthy lifespans. This call to action comes at a pivotal moment, as global life expectancy has more than doubled to 71 years, yet the gap between healthspan and lifespan has widened to 9.6 years, meaning many people spend nearly a decade of their lives in poor health as a result of chronic diseases.
Speaking ahead of the event, H.E. Mansoor Ibrahim Al Mansoori, Chairman of DoH stated "We are delivering personalised and preventive health solutions that empower people to live longer, healthier, and more fulfilling lives. Because health knows no boundaries, we are inviting the world to co-create the next era of health, underpinned by collaboration, driven by data and transformative technology such as AI. From Abu Dhabi to the world, we are building an intelligent, integrated health system that scales globally and serves locally."
With world-class research institutions, strategic investments, and artificial intelligence (AI)-driven medical advancements, Abu Dhabi is transforming the healthcare industry by advancing research, enabling strategic global partnerships, and ensuring equitable access to healthy life-extending medical innovations. The emirate's focus on AI-powered medical research is enhancing disease prediction and precision therapeutics, further solidifying its position as a leader in healthcare innovation.
This global leadership is built on a foundation of concrete action. Abu Dhabi's commitment to healthy longevity is already translating into impact. The emirate recently licensed the Institute for Healthier Living Abu Dhabi (IHLAD) as the world's first Healthy Longevity Medicine Centre, offering AI-enabled, personalised care to extend healthy lifespan, manage chronic diseases, and support mental well-being and lifestyle transformation. This was followed by the launch of the Healthy Longevity Innovation Forum and the introduction of the region's first regulatory framework for longevity-focused medical centres—setting a new benchmark for healthcare governance. Together with initiatives like the Healthy Longevity Symposium hosted by the Khalifa University and a growing network of global research partnerships, these efforts firmly position Abu Dhabi at the forefront of reimagining how societies approach aging, prevention, and extended health spans. The initiative, developed with and for the world, will create a roadmap that advances AI-powered diagnostics, genomics-based healthcare, and personalised treatment strategies, ensuring more people can benefit from extended healthy lifespans.
Key highlights to expect:
The initiative will be a highlight of ADGHW, scheduled to take place from 15 – 17 April 2025. The three-day event provides a platform to exchange insights, address critical healthcare challenges, and build partnerships that drive meaningful progress in global health and well-being. The event is expected to attract more than 200 speakers, 15,000 visitors, 1,900 delegates and 150 exhibitors from 90 countries.
Further details regarding the initiative will be announced at ADGHW.
ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care.
Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
About Abu Dhabi Global Health Week:
Abu Dhabi Global Health Week (ADGHW) is a major government-led initiative by the Department of Health – Abu Dhabi (DoH). It drives transformative innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being'. ADGHW serves as a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care. Held with and for the world, ADGHW is a platform for open, inclusive exchange, and joint action.
ADGHW welcomes entrepreneurs, policymakers, researchers, innovators, and investors to transform ideas into action, and collaborate around topics like advancing precision care and building a resilient technology-driven ecosystem. ADGHW 2025 proudly collaborates with key strategic partners, including Foundation Partner, M42 and Global Health and Longevity Champion, PureHealth. Additional exhibitors and sponsors include Burjeel, GSK, Johnson & Johnson, Lilly, Microsoft, Novo Nordisk, Viatris, Novartis, Roche, Cleveland Clinic Abu Dhabi, Deloitte, Gilead, Juvenescence, NYU Abu Dhabi and Pfizer, united in their commitment to advancing the future of healthcare and life sciences.
For more information on ADGHW, visit https://www.adghw.com/
For media registration visit,
For ADGHW media inquiries or interview opportunities, please contact:
Maroun Farah, Senior Media Relations Manager, Weber Shandwick
E: mfarah@webershandwick.com
T: +971 55 166 2557
About the Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforces standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system. For further information on DOH, visit https://www.doh.gov.ae/ and follow on Twitter, Instagram, Facebook, LinkedIn and YouTube.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
Korea Herald
2 days ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact
Korea Herald
3 days ago
- Korea Herald
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.
